Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and PuppiesBusiness Wire • 08/13/26
Zoetis Sees Softer Pet Health Demand, But Adapting Commercial Strategy to Navigate HeadwindsBenzinga • 08/06/26
Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating OfficerBusiness Wire • 08/06/26
Gear Up for Zoetis (ZTS) Q2 Earnings: Wall Street Estimates for Key MetricsZacks Investment Research • 08/04/26
ZTS Set to Report Q2 Earnings: Here's What Investors Should ExpectZacks Investment Research • 08/03/26
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 07/30/26
Zoetis (ZTS) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 07/27/26
ZTS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Zoetis Inc. Investors to Secure Counsel Before Important July 27 Deadline in Securities Class Action - ZTSNewsfile Corp • 07/27/26